RxDoctor Payments Data

Loretta Que, MD

Pulmonary Disease · Durham, NCNPI 1245314137

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,801 of the $14,007 with a category attached, or 91.4%. Sanofi accounts for 80.8% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $11,300, more than ten times the $12 reported in 2020.

$14,007in general payments, 2019–2025

Across 8 payments — averaging $1750.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$11K
  • Merck$3K
  • AstraZeneca$12
$1,313,572in research payments, 2019–2025

Across 188 payments — averaging $6987.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$454K
  • AstraZeneca$412K
  • Astrazeneca UK Limited$194K
  • Amgen$119K
  • Sanofi US Services Inc.$98K
  • GSK$19K
  • plus $16K from 1 others

What the payments were for

  • Consulting fees$12,80191%
  • Travel & lodging$1,0397%
  • Food & beverage$1551%
  • Education$120%

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi5$11,321
Merck2$2,674
AstraZeneca1$12

How this compares

$14,007 in reported general payments places this provider in the 80th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,804
Medicare patients
84
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab28$319,570
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$95,000
Fasenra PenBenralizumab16$94,208
Dupixent SyringeDupilumab13$50,594
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$22,501
Breo ElliptaFluticasone/Vilanterol16$9,348
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,498
SymbicortBudesonide/Formoterol Fumarate20$6,016
Serevent DiskusSalmeterol Xinafoate12$5,263
Albuterol Sulfate HfaAlbuterol Sulfate53$1,844
Ipratropium Bromide22$538
Azithromycin23$492
Montelukast Sodium51$319
Omeprazole26$270
Fluticasone Propionate17$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$12$6,01620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →